Management of acute cardiac failure with mechanical assist: experience with the ABIOMED BVS 5000

Samuels, Louis E.; Holmes, Elena C.; Thomas, Matthew J. W.; Entwistle, John W.; Morris, Rohinton J.; Narula, Jaguat; Wechsler, Andrew S.

doi:10.1016/s0003-4975(00)02644-8

Cited by 109 publications

(48 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a study of 45 patients with the ABIOMED BVS 5000 from 1994 to 2000, 31% of the patients survived to discharge. 14 In a different series published in 1999, Helman et The present study underscores the importance of understanding risk factors for mortality and major morbidity after VAD implantation. The characteristics outlined in the multivariable model can be used to identify patients who are at higher risk for morbidity and mortality post-VAD implantation, allowing more informed clinical decisions.…”

Section: Discussionmentioning

confidence: 53%

“…Pulsatile pumps often are easier to implant because of advances in cannulation and are less likely to need to be replaced. [12][13][14] Because of these advances, there may be fewer problems with bleeding, infections, hemolysis, and embolic events. Second, patient management also has advanced, with centers using protocols for anticoagulation and antibiotics that may have evolved over the years.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Decade of Short-Term Outcomes in Post–Cardiac Surgery Ventricular Assist Device Implantation

et al. 2007

View full text Add to dashboard Cite

Background-Previous studies showed 75% mortality before hospital discharge in patients with a ventricular assist device (VAD) placed for post-cardiac surgery shock. We examined a large national clinical database to assess trends in the incidence of post-cardiac surgery shock requiring VAD implantation, survival rates, and risk factors for mortality. Methods and Results-We identified patients undergoing a VAD procedure after cardiac surgery at US hospitals participating in the Society of Thoracic Surgeons' National Cardiac Database during the years 1995 to 2004. Baseline characteristics and operative outcomes were analyzed in 2.5-year increments. Logistic regression modeling was performed to provide risk-adjusted operative mortality and morbidity odds ratios. A total of 5735 patients had a VAD placed during the 10-year period (0.3% cardiac surgeries). Overall survival rate to discharge after VAD placement was 54.1%. With the earliest period (January 1995 through June 1997) used as reference, the mortality odds ratio declined to 0.72 (July 1997 through December 1999) and eventually to 0.41 (July 2002through December 2004 PϽ0.0001). The combined mortality/morbidity odds ratio also declined, to 0.84 and 0.48 over identical periods (PϽ0.0001). Preoperative characteristics associated with increased mortality were urgency of procedure, reoperation, renal failure, myocardial infarction, aortic stenosis, female sex, race, peripheral vascular disease, New York Heart Association class IV, cardiogenic shock, left main coronary stenosis, and valve procedure (c indexϭ0.755). Conclusions-After

show abstract

Section: Discussionmentioning

confidence: 53%

Section: Discussionmentioning

confidence: 99%

A Decade of Short-Term Outcomes in Post–Cardiac Surgery Ventricular Assist Device Implantation

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Samuels et al [15] reported 31% hospital discharge for patients with acute cardiac failure supported by the ABIOMED BVS system. CentriMag has been used for several indications, including post-cardiotomy failure leading to a successful weaning rate of 83% and a discharge rate of 45%.…”

Section: Discussionmentioning

confidence: 99%

The Levitronix CentriMag ventricular assist device as a bridge to decision in patients with end-stage heart failure: Our single-center experience

Rabuş¹

2017

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

Rabuş MB, Salihi S, Hasanov S, Fedakar A, Çevirme D, Balkanay M. The Levitronix CentriMag ventricular assist device as a bridge to decision in patients with end-stage heart failure: Our single-center experience. Turk Gogus Kalp Dama 2017;25(4):543-9. ABSTRACTBackground: In this study, we report early outcomes of Levitronix CentriMag device implantation for bridge to decision for patients with end-stage heart failure in a single center.

show abstract

“…Several types of blood pumps have been used for temporary mechanical circulatory support (18)(19)(20)(21)(22)(23)(24)(25). These include pneumatic systems such as the Abiomed BVS 5000 and the AB5000 (Abiomed, Inc., Danvers, MA).…”

Section: Commentmentioning

confidence: 99%

In Vivo Testing of a Novel Blood Pump for Short-Term Extracorporeal Life Support

Teman

Demos

Bryner

et al. 2013

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Management of acute cardiac failure with mechanical assist: experience with the ABIOMED BVS 5000

Cited by 109 publications

References 15 publications

A Decade of Short-Term Outcomes in Post–Cardiac Surgery Ventricular Assist Device Implantation

A Decade of Short-Term Outcomes in Post–Cardiac Surgery Ventricular Assist Device Implantation

The Levitronix CentriMag ventricular assist device as a bridge to decision in patients with end-stage heart failure: Our single-center experience

In Vivo Testing of a Novel Blood Pump for Short-Term Extracorporeal Life Support

Contact Info

Product

Resources

About